Company Filing History:
Years Active: 2025
Title: Kana Kohmoto: Innovator in Cancer Therapeutics
Introduction
Kana Kohmoto is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer therapeutics, showcasing her innovative spirit and dedication to improving healthcare.
Latest Patents
Kana Kohmoto holds a patent for a conjugate and cancer therapeutic agent. This invention involves a conjugate that includes a deferoxamine-type compound, which is selected from the group consisting of deferoxamine or an ion or salt thereof, along with a derivative thereof. The conjugate is combined with a biocompatible polymer that contains a first biocompatible polymer chain and a second biocompatible polymer chain that differs from the first. This innovative approach aims to enhance the effectiveness of cancer treatments.
Career Highlights
Throughout her career, Kana has worked with esteemed institutions such as the Tokyo Institute of Technology and Sbi Pharmaceuticals Co., Ltd. Her work in these organizations has allowed her to develop her ideas and contribute to significant advancements in medical science.
Collaborations
Kana has collaborated with notable colleagues, including Nobuhiro Nishiyama and Takahiro Nomoto. These partnerships have fostered a creative environment that encourages the exchange of ideas and expertise.
Conclusion
Kana Kohmoto is a trailblazer in the field of cancer therapeutics, with her innovative patent and collaborative efforts paving the way for future advancements. Her work exemplifies the impact of dedicated inventors in the medical field.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.